199 related articles for article (PubMed ID: 6241755)
1. Progressive exposure of E-neoantigen associated with degradation of crosslinked fibrin by plasmin in vitro.
Stegnar M; Chen JP
Thromb Haemost; 1984 Dec; 52(3):315-20. PubMed ID: 6241755
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunoassay of fragment E-related neoantigen: validation studies and clinical application.
Chen JP; Hanna WT; Williams TK; Krauss S
Br J Haematol; 1984 May; 57(1):133-44. PubMed ID: 6722032
[TBL] [Abstract][Full Text] [Related]
3. Degradation pathway of fibrinogen by plasmin.
Budzynski AZ; Marder VJ
Thromb Haemost; 1977 Dec; 38(4):793-800. PubMed ID: 146273
[TBL] [Abstract][Full Text] [Related]
4. Immunobiology of fibrinogen. Emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo.
Plow E; Edgington TS
J Clin Invest; 1973 Feb; 52(2):273-82. PubMed ID: 4119160
[TBL] [Abstract][Full Text] [Related]
5. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
[TBL] [Abstract][Full Text] [Related]
6. Terminal plasmin degradation products D and E of duck fibrinogen and their effect on polymerization of fibrin.
Krajewski T; Nowak P; Cierniewski C
Acta Biochim Pol; 1985; 32(2):144-54. PubMed ID: 4036448
[TBL] [Abstract][Full Text] [Related]
7. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
[TBL] [Abstract][Full Text] [Related]
8. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond.
Bini A; Itoh Y; Kudryk BJ; Nagase H
Biochemistry; 1996 Oct; 35(40):13056-63. PubMed ID: 8855941
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies.
Raut S; Gaffney PJ
Thromb Haemost; 1996 Jul; 76(1):56-64. PubMed ID: 8819252
[TBL] [Abstract][Full Text] [Related]
10. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Carroll RC; Lockhart MS; Taylor FB
J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
[TBL] [Abstract][Full Text] [Related]
11. A molecular model of plasmic degradation of crosslinked fibrin.
Francis CW; Marder VJ
Semin Thromb Hemost; 1982 Jan; 8(1):25-35. PubMed ID: 6460319
[TBL] [Abstract][Full Text] [Related]
12. Proceedings: Characterisation of a soluble high molecular weight e fragment released by plasmin from cross-linked fibrin.
Lane DA; Brasher M; Kakkar VV; Gaffney PJ
Thromb Diath Haemorrh; 1975 Sep; 34(1):325. PubMed ID: 127399
[No Abstract] [Full Text] [Related]
13. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
Rozenfel'd MA; Leonova VB; Khavkina LS
Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
[TBL] [Abstract][Full Text] [Related]
14. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure.
Francis CW; Marder VJ; Barlow GH
J Clin Invest; 1980 Nov; 66(5):1033-43. PubMed ID: 6448866
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
[TBL] [Abstract][Full Text] [Related]
16. Immune responses to the cleavage-associated neoantigens of fibrinogen in man. Identification and characterization of humoral antibodies specific for cleavage fragments.
Plow EF; Edgington TS
J Clin Invest; 1975 Dec; 56(6):1509-18. PubMed ID: 53241
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
[TBL] [Abstract][Full Text] [Related]
18. The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests.
Brenner B; Francis CW; Marder VJ
J Lab Clin Med; 1989 Jun; 113(6):682-8. PubMed ID: 2732616
[TBL] [Abstract][Full Text] [Related]
19. A simple rapid method for the purification of D and E fragments of fibrinogen degradation by plasmin.
Carvajal Z; Arocha-Pinango CL
Haematologica; 1983; 68(3):336-40. PubMed ID: 6224723
[No Abstract] [Full Text] [Related]
20. Orientation of the carboxy-terminal regions of fibrin gamma chain dimers determined from the crosslinked products formed in mixtures of fibrin, fragment D, and factor XIIIa.
Siebenlist KR; Meh DA; Wall JS; Hainfeld JF; Mosesson MW
Thromb Haemost; 1995 Oct; 74(4):1113-9. PubMed ID: 8560422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
